title: Therapeutic advancements in multiple myeloma.
abstract: Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. Moreover, novel strategies of treatment such as consolidation and maintenance are being used to further implement responses. Finally, a number of new drugs such as carfilzomib and pomalidomide are already in clinical practice, making the future of myeloma patients brighter.
authors.affiliation: Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte" , Siena , Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.affiliation: Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte" , Siena , Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Candi
authors.affiliation: Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte" , Siena , Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Papini
authors.affiliation: Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte" , Siena , Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
keywords: IMID’s; bortezomib; elderly; multiple myeloma; new therapies; young